Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 95-98

  Chang, Hong ^a   Trieu, Young ^a   Qi, Xiaoying ^a   Jiang, Nan N ^a   Xu, Wei ^a   Reece, Donna ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

1q21(CKS1B) gain; Bortezomib; Cytogenetics; FISH; Multiple myeloma

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; STEROID; THALIDOMIDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER STAGING; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC RISK; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BORONIC ACIDS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 78650169662     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.002     Document Type: Article

References (30)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
2. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
3. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
4. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
5. Jagannath S., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
6. Sagaster V., Ludwig H., Kaufmann H., Odelga V., Zojer N., Ackermann J., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21:164-168.
7. Chang H., Trieu Y., Qi X.Y., Xu W., Stewart K. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007, 33:779-782.
8. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
9. Gutierrez N.C., Castellanos M.V., Martin M.L., Mateos M.V., HernandezJM, Fernandez M., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007, 21:143-150.
10. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
11. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., et al. Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
12. Chang H., Yi Q.C., Yi Q.L., Reece D., Stewart A.K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005, 105:358-360.
13. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 and an aggressive clinical course in multiple myeloma. Hematology 2005, 10:117-126.
14. Hanamura I., Stewart J.P., Huang Y., Zhan F.H., Santra M., Sawyer J.R., et al. Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood 2006, 108:1724-1732.
15. Chang H., Qi X.Y., Trieu Y., Xu W., Reader J.C., Ning Y., et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression free survival post-autologous stem cell transplantation. Br J Haematol 2006, 135:486-491.
16. Fonseca R., Van Wier S.A., Chng W.J., Ketterling R., Lacy M.Q., Dispenzieri A., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006, 20:2034-2040.
17. Shaughnessy J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
18. Chang H., Ning Y., Qi Q.Y., Yeung J., Xu W. Chromosome 1p21 deletion is a novel prognostic factor in patients with multiple myeloma. Br J Haematol 2007, 139:51-54.
19. Jaksic W., Trudel S., Chang H., Trieu Y., Qi X., Mikhael J., et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005, 23:7069-7073.
20. Chang H., Li D., Zhuang L., Nie E., Bouman D., Stewart A.K., et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk lymphoma 2004, 45:965-969.
21. Barlogie B., Anaissie E., van Rhee F., Haessler J., Hollmig K., Pineda-Roman M., et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007, 138:176-185.
22. Shaughnessy J.D., Zhou Y., Haessler J., van Rhee F., Anaissie E., Nair B., et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009, 147:347-351.
23. Richardson P.G., Xie W., Mitsiades C., Chanan-Khan A.A., Lonial S., Hassoun H., et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
24. Carrasco D.R., Tonon G., Huang Y., Zhang Y., Sinha R., Feng B., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9:313-325.
25. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
26. Egan E.A., Solomon N.J. Cyclin-stimulated binding of Cks proteins to cyclin-dependent kinases. Mol Cell Biol 1998, 7:3659-3667.
27. Ganoth D., Bornstein G., Ko T.K., Larsen B., Tyers M., Pagano M., et al. The cell-cycle regulatory protein Cks1 is required for SCFSKP2-mediated ubiquitinylation of p27. Nat Cell Biol 2001, 3:321-324.
28. Bloom J., Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003, 13:41-47.
29. Zhan F., Colla S., Wu X., Chen B., Stewart J.P., Michael Kuehl W., et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007, 109:4995-5001.
30. Tian E., Landowski T.H., Stephens O.W., Yaccoby S., Barlogie B., Shaughnessy J.D. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. Mol Cancer Ther 2008, 7:500-509.